Patent · US Active

CAMK2D antisense oligonucleotides and uses thereof

US11058767B2 · kind B2 · utility

0Cited by

3References

17Claims

0Family size

Assignees

Bristol-Myers Squibb Company · US
ROCHE INNOVATION CENTER COPENHAGEN A/S · DK

Inventors

Richard E. Olson · Wilmington, US
Brian R. Anderson · Princeton, US
Peter Hagedorn · Hørsholm, DK
Marianne Lerbech Jensen · Køge, DK
Ivar M. McDonald · East Haddam, US
Stephen E. Mercer · Wilmington, US

Key dates

Filing date	Feb 21, 2019
Grant date	Jul 13, 2021
Priority date	—
Expiry date	Feb 21, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y207/11017
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.